| Publikationstyp: | Konferenz: Sonstiges |
| Art der Begutachtung: | Peer review (Abstract) |
| Titel: | Emodin, a compound with acclaimed antidiabetic potential, deteriorates glucose tolerance in obese mice |
| Autor/-in: | Abu Eid, S. Adams, M. Scherer, T. Torres-Gómez, H. Hackl, M.T. Riedl, R. Luger, A. Fürnsinn, C. |
| et. al: | No |
| DOI: | 10.1007/s00125-016-4046-9 |
| Erschienen in: | Diabetologia |
| Tagungsband: | Abstracts of 52nd EASD Annual Meeting |
| Band(Heft): | 59 |
| Heft: | Suppl 1 |
| Seite(n): | S343 |
| Angaben zur Konferenz: | 52nd EASD Annual Meeting, Munich, Germany, 12–16 September 2016 |
| Erscheinungsdatum: | Sep-2016 |
| Verlag / Hrsg. Institution: | Springer |
| ISSN: | 0012-186X 1432-0428 |
| Sprache: | Englisch |
| Fachgebiet (DDC): | 615: Pharmakologie und Therapeutik 616: Innere Medizin und Krankheiten |
| Zusammenfassung: | Emodin is found in herbal remedies used in Traditional Chinese Medicine. Alongside its undisputed laxative action, emodin has been reported to lower blood glucose in hyperglycaemic rodents. Although purely experimental, these results are heralded in non-scientific (online-) sources to promote sales of emodin-containing herbal products as a natural cure for diabetes. While emodin-induced glucose lowering has been attributed to a surprising multitude of molecular mechanisms (activation of PPARγ, inhibition of 11β-HSD, activation of AMPK, etc.), little effort has been made to sort out, whether emodin merely acts via loss of appetite and body weight. |
| URI: | https://digitalcollection.zhaw.ch/handle/11475/30073 |
| Volltext Version: | Publizierte Version |
| Lizenz (gemäss Verlagsvertrag): | Lizenz gemäss Verlagsvertrag |
| Departement: | Life Sciences und Facility Management |
| Organisationseinheit: | Institut für Chemie und Biotechnologie (ICBT) |
| Enthalten in den Sammlungen: | Publikationen Life Sciences und Facility Management |
Dateien zu dieser Ressource:
Es gibt keine Dateien zu dieser Ressource.
Zur Langanzeige
Abu Eid, S., Adams, M., Scherer, T., Torres-Gómez, H., Hackl, M. T., Riedl, R., Luger, A., & Fürnsinn, C. (2016). Emodin, a compound with acclaimed antidiabetic potential, deteriorates glucose tolerance in obese mice [Conference presentation]. Diabetologia, 59(Suppl 1), S343. https://doi.org/10.1007/s00125-016-4046-9
Abu Eid, S. et al. (2016) ‘Emodin, a compound with acclaimed antidiabetic potential, deteriorates glucose tolerance in obese mice’, in Diabetologia. Springer, p. S343. Available at: https://doi.org/10.1007/s00125-016-4046-9.
S. Abu Eid et al., “Emodin, a compound with acclaimed antidiabetic potential, deteriorates glucose tolerance in obese mice,” in Diabetologia, Sep. 2016, vol. 59, no. Suppl 1, p. S343. doi: 10.1007/s00125-016-4046-9.
ABU EID, S., M. ADAMS, T. SCHERER, H. TORRES-GÓMEZ, M.T. HACKL, R. RIEDL, A. LUGER und C. FÜRNSINN, 2016. Emodin, a compound with acclaimed antidiabetic potential, deteriorates glucose tolerance in obese mice. In: Diabetologia. Conference presentation. Springer. September 2016. S. S343
Abu Eid, S., M. Adams, T. Scherer, H. Torres-Gómez, M.T. Hackl, R. Riedl, A. Luger, and C. Fürnsinn. 2016. “Emodin, a Compound with Acclaimed Antidiabetic Potential, Deteriorates Glucose Tolerance in Obese Mice.” Conference presentation. In Diabetologia, 59:S343. Springer. https://doi.org/10.1007/s00125-016-4046-9.
Abu Eid, S., et al. “Emodin, a Compound with Acclaimed Antidiabetic Potential, Deteriorates Glucose Tolerance in Obese Mice.” Diabetologia, vol. 59, no. Suppl 1, Springer, 2016, p. S343, https://doi.org/10.1007/s00125-016-4046-9.
Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt, soweit nicht anderweitig angezeigt.